Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib.
Gambacorti-Passerini
Carlo
C
Professor of Internal Medicine and OncologyNCI/University of Milano Bicocca, Italy and JGH, McGill University, Montreal, Canada. carlo.gambacorti@unimib.it.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002875:Chromosomes / Q000187:drug effects; D020732:Cytogenetic Analysis / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate